SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy.
BioJapan Congress 2024
SOPHiA GENETICS™ is excited to be for the first time part of the BioJapan Congress. You will have the chance to chat with our team at booth to discuss our solutions and our universal SOPHiA DDM™ Platform. Asia‘s Premier Hybrid Partnering Event Oct 9 Wed - 11 Fri....
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials.
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
The global collective intelligence network aims to accelerate precision oncology research and care.
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
SOPHiA GENETICS Announces It Joins the European Liquid Biopsy Society at ECP 2024
The Society brings together over 87 academic and industry leaders in liquid biopsy.
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in development by Boundless Bio.
SOPHiA GENETICS Unveils New Generation of the SOPHiA DDM™ Platform at Morgan Stanley Healthcare Conference 2024
New generation of SOPHiA DDM™ integrates latest advancements in data processing and technology to deliver elevated experience and capabilities to customers.
SOPHiA GENETICS to Present at the 22nd Annual Morgan Stanley Healthcare Conference and 9th Annual TD Cowen FutureHealth Conference
BOSTON, United States and ROLLE, Switzerland, August 28, 2024 — SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced presentations at the 22nd Annual Morgan Stanley Healthcare Conference and the 9th Annual TD Cowen...
Customer Spotlight: Laboratory of Genetics and Genomics, Cagliari
We recently spoke with Manuela Badiali, Rita Congiu, and Stefania Murru from the Laboratory of Genetics and Genomics, Microcitemico Pediatric Hospital – A. Cao, Cagliari, about how SOPHiA DDM™ RNAtarget Technology has helped them optimize their variant analysis workflow.
SOPHiA DDM™ Platform Certified Under IVDR
Regulatory milestone validates the SOPHiA DDM™ Platform as diagnostic tool in select markets.
Enhancing variant interpretation: Obtaining answers from a vast universe of data
Pinpointing pathogenic mutations from large, complex datasets can be difficult, time-consuming, and somewhat overwhelming. So, how can you streamline your genomic analysis, to make it quicker, easier, and more efficient? In this webinar you will learn how Alamut™...
SOPHiA GENETICS Reports Second Quarter 2024 Results
Strength in U.S. Growth Offset by Challenges in BioPharma and EMEA; Strong Cost Management Buffers Loss
